Penn Center for Myeloproliferative Neoplasms
Saar I Gill
Saar I Gill
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 650 213 6249
Lab: (215) 573-4015
Lab: (215) 573-4015
Education:
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent linkMBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Description of Clinical Expertise
Blood and Marrow TransplantationLeukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Lymphoproliferative Neoplasms
Bone Marrow Failure
Description of Research Expertise
Tumor ImmunologyChimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry
Selected Publications
McFarland AG, Ooi SK, Tafuri D, Kamali E, Cooper N, Cook EJ, Reddy S, Jarocha D, Wellhausen N, Gill SI, Roche AM, Fraietta JA, Bushman FD, Herbst F.: An integrated enzymatic and computational pipeline for quantifying off-target base-editing. bioRxiv Aug 2025.Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble AJ, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI.: International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AML. Blood Adv Aug 2025.
Mellors PW, Lange AN, Casino Remondo B, Shestov M, Planer JD, Peterson AR, Ying Y, Zhou S, Christie JD, Diamond JM, Cantu E, Basil MC, Gill S.: Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome. JCI Insight 10: e176596, Apr 2025.
Sande CM, Chen S, Mitchell DV, Lin P, Abraham DM, Cheng JM, Gebhard T, Deolikar RJ, Freeman C, Zhou M, Kumar S, Bowman M, Bowman RL, Zheng S, Munkhbileg B, Chen Q, Stanley NL, Guo K, Lapite A, Hausler R, Taylor DM, Corines J, Morrissette JJ, Lieberman DB, Yang G, Shestova O, Gill S, Zheng J, Smith-Simmer K, Banaszak LG, Shoger KN, Reinig EF, Peterson M, Nicholas P, Walne AJ, Dokal I, Rosenheck JP, Oetjen KA, Link DC, Gelman AE, Reilly CR, Dutta R, Lindsley RC, Brundige KJ, Agarwal S, Bertuch AA, Churpek JE, Tague LK, Johnson FB, Olson TS, Babushok DV.: ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders. J Clin Invest 135: e181659, Apr 2025.
Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, Nagar K, Griffin C, Lian L, Yashiro-Ohtani Y, Ross K, Sloas C, Ball M, Schott B, Sonawane P, Cornell L, Blumenthal D, Chhum S, Minutolo N, Ciccaglione K, Shaw L, Zentner I, Levitsky H, Shestova O, Gill S, Varghese B, Cushing D, Ceeraz DeLong S, Abramson S, Condamine T, Klichinsky M.: Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun 16: 2692, Mar 2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9: 533-544, Feb 2025.
Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, Nagar K, Griffin C, Lian L, Yashiro-Ohtani Y, Ross K, Sloas C, Ball M, Schott B, Sonawane P, Cornell L, Blumenthal D, Chhum S, Minutolo N, Ciccaglione K, Shaw L, Zentner I, Levitsky H, Shestova O, Gill S, Varghese B, Cushing D, Ceeraz DeLong S, Abramson S, Condamine T, Klichinsky M.: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun 16: 706, Jan 2025.
Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, Schmierer M, Kremp M, Ball M, Qureshi R, Schott BH, Sonawane P, DeLong SC, Christiano M, Swaby RF, Abramson S, Locke K, Barton D, Kennedy E, Gill S, Cushing D, Klichinsky M, Condamine T, Abdou Y.: CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med 2025.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med 2025.
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther 2025.